Regulatory delay: The FDA extended its review of Biogen’s Leqembi Iqlik Alzheimer’s therapy by three months to August 24, 2026, to assess additional submitted data. Investor reaction: Biogen’s stock ...
Biogen Inc. BIIB shares are trading higher on Friday as the company is continuing its FDA review process for Leqembi Iqlik ...
The FDA has extended the review period for its supplemental biologics license application of Leqembi Iqlik by three months to Aug. 24.
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
For Roslyn Mannon, MD, a single patient experience inspired her path to nephrology.“The patient talked passionately about how ...
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is ...
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
Despite challenges for approval and access, regenerative therapies for retinal diseases may not be far away from becoming ...
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...
Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results